Bexion Pharmaceuticals
Aug 17, 2018
KEY CLINICAL OUTCOMES
Bexion Pharmaceuticals’ Early-Stage Cancer Drug, BXQ-350 Hailed as Game Changer For the Treatment of solid tumors and gliomas Bexion Pharmaceuticals’ investigational cancer treatment, BXQ-350, is receiving lots of mainstream media coverage as a potential game-changer. BXQ-350 is a formulation of a syntheticall...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
